Helmholtz-Alberta Initiative – Infectious Disease Research
The main objective of the collaborative HAI program in the field of Infectious Disease Research is to tackle unmet needs in the development of preventative vaccines and treatments of liver disease caused by hepatitis B and C viruses.
Complementary world-class expertise and resources
Currently there are more than half a billion people chronically infected with HBV and HCV. The majority of individuals infected become chronic carriers of these infections. By joining complementary world-class expertise and resources in the fight against hepatitis, the University of Alberta and Helmholtz Association will contribute to confining the spread of hepatitis and prevent future infections, help the current hepatitis patients, and reduce the disease’s immense healthcare economic burdens.
Integrated education and training program
In addition to its research program, the HAI-IDR also contains an integrated education and training program for the next generation of scientists, and promotes technology transfer to benefit Alberta, Germany, and the world. In the long run, HAI-IDR envisions expanding into other viral diseases and helping meet emerging and future infectious diseases head on.
The research projects currently focus on:
- Carlos A. Guzmán, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany
- Ulrich Kalinke, Thomas Pietschmann, Twincore - Centre for Experimental and Clinical Infection Research (Twincore), Hannover, Germany; a joint venture between the Hanover Medical School and the HZI
- Rolf Müller, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Saarbrucken, Germany; a joint institution of Saarland University and the HZI
- Ulrike Protzer, Helmholtz Zentrum München - German Research Center for Environmental Health (HMGU)
- David Evans, Michael Houghton, D. Lorne Tyrrell, Michele Barry, Tom Hobman, Luis Schang, Department of Medical Microbiology and Immunology, University of Alberta (U of A), Edmonton, Canada
- David Evans, D. Lorne Tyrrell, Luis Schang, Tom Hobman, Li Ka Shing Institute of Virology (LKSIOV), Edmonton, Canada
- Luis Schang, Department of Biochemistry, University of Alberta (U of A), Edmonton, Canada
- Mary Hitt, Department of Oncology, University of Alberta (U of A), Edmonton, Canada
- Tom Hobman, Department of Cell Biology, University of Alberta (U of A), Edmonton, Canada
- D. Lorne Tyrrell, KMT Hepatech; a spin-off company from the U of A
- Vaccinology and applied Microbiology- Prof. Dr. Carlos A. Guzmán
D. Lorne Tyrrell, MD PhD Li Ka Shing Institute of Virology University of Alberta Edmonton, Canada; Carlos A. Guzmán, MD PhD, Research group Vaccinology, HZI